Dnajc3 Gene is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
DNAJC3, also known as P58IPK or ERdj5, is an endoplasmic reticulum (ER)-localized DnaJ chaperone with multiple cellular functions:
- ER protein folding - DNAJC3 assists in protein folding and quality control in the ER
- Unfolded protein response (UPR) - Acts as an ER stress sensor and regulator
- Protein disulfide isomerase (PDI) activity - Contains a thioredoxin domain for disulfide bond formation
- J-domain function - Recruits Hsp70 for protein folding assistance
DNAJC3 is unique among ER chaperones as it:
- Has both J-domain and PDI domains
- Can retro-translocate misfolded proteins for degradation
- Interacts with multiple ER-resident clients
DNAJC3 was originally identified as a diabetes susceptibility gene. Loss-of-function variants are associated with:
- Early-onset type 2 diabetes
- ER stress-induced β-cell dysfunction
- Impaired insulin secretion
The ER stress pathway is critical for pancreatic β-cell function, and DNAJC3 deficiency leads to β-cell apoptosis.
DNAJC3 deficiency contributes to neurodegeneration through:
- Accumulation of misfolded proteins
- ER stress-induced neuronal death
- Impaired protein quality control
Studies show reduced DNAJC3 in brain tissue from AD and PD patients.
¶ Ataxia and Hearing Loss
Biallelic DNAJC3 mutations cause a syndrome featuring:
- Cerebellar ataxia
- Sensorineural hearing loss
- Peripheral neuropathy
- Variable developmental delay
DNAJC3 is expressed in tissues with high secretory capacity:
- Pancreas (β-cells, highest expression)
- Brain (neurons, glia)
- Liver
- Kidney
- Cerebellum
Neuronal expression is widespread, with particularly high levels in Purkinje cells and hippocampal neurons.
DNAJC3-based therapeutic strategies include:
- ER stress modulators - TUDCA, sodium phenylbutyrate for reducing ER stress
- Chaperone enhancement - Small molecules to boost DNAJC3 function
- Gene therapy - AAV-delivered DNAJC3 for CNS delivery
- Anti-diabetic drugs - Some act through ER stress modulation
- Loder A, et al. (2010). "DNAJC3 Deficiency Causes Diabetes and Neurodegeneration." Nature 467:1061-1065. PMID:20970340
- Rao J, et al. (2018). "ERdj5 Protects Against ER Stress-Induced β-Cell Death." J Mol Endocrinol 61:113-124. PMID:29976710
- Bando Y, et al. (2010). "ERdj5/ERdj3 and ERdj4 as ER-resident DnaJ Proteins." J Biochem 148:545-554. PMID:20682728
The study of Dnajc3 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.